WATERTOWN, Mass .– (BUSINESS WIRE) – Aug 23, 2021–
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver disease, today announced the election of Yujiro S. Hata to its board of directors.
Yujiro S. Hata, Board of Directors, Enanta Pharmaceuticals (Photo: Business Wire)
“We are delighted to welcome Yujiro Hata to our Board of Directors,” said Jay R. Luly, Ph.D., President and CEO of Enanta Pharmaceuticals. “His in-depth expertise in business and corporate development, as well as his experience as a senior executive and independent director of several public and private biotechnology companies, will bring additional depth to our Board of Directors. Yujiro’s knowledge will be particularly valuable as we continue to explore combination therapies to advance our clinical pipeline in key therapeutic areas.
“I am delighted to join Enanta as a member of its board of directors. Enanta’s proven, chemistry-driven approach to creating world-class small molecule drugs has enabled the company to develop a strong and differentiated portfolio of product candidates in the areas of virology and liver disease ”, commented Mr. Hata. “I look forward to working with the team, especially in the coming year when the combination of clinical data readings on Respiratory Syncytial Virus, Hepatitis B Virus, SARS-CoV- 2 and non-alcoholic steatohepatitis has the potential to be truly transformative. “
Mr. Hata has over 20 years of experience in building businesses that have developed innovative therapies. He is currently the Founder and CEO of IDEAYA Biosciences, an oncology-focused precision medicine company, which he founded in 2015. Under his leadership, IDEAYA formed a global partnership with GlaxoSmithKline to develop synthetic lethality programs , an emerging field in oncology. From 2015 to 2018, Mr. Hata was an executive in residence at 5AM Ventures. From 2014 to August 2015, he was COO at Flexus Biosciences where he helped lead the company when it was acquired by Bristol-Myers Squibb in April 2015, then he was COO at RAPT Therapeutics (formerly FLX Bio ). Prior to that, Mr. Hata held positions of increasing responsibility, most recently as Vice President, Corporate Development and Strategy, at Onyx Pharmaceuticals, when the company obtained approvals for KYPROLIS® and STIVARGA®, leading to its acquisition by Amgen in October 2013. Previously Mr. Hata held business development positions at Enanta and at ImClone Systems, now a subsidiary of Eli Lilly and Company.
Mr. Hata serves on the boards of Xencor and Expansion Therapeutics and is a member of the board of directors of the Moores Cancer Center at the University of California at San Diego. He received his MBA from the University of Pennsylvania, his BA in Chemistry from Colorado College, and completed undergraduate studies in Chemistry and Biology at the University of Oxford.
Enanta uses its robust chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver disease. Enanta’s research and development efforts have produced clinical candidates for the following target diseases: respiratory syncytial virus (RSV), hepatitis B virus (HBV), non-alcoholic steatohepatitis (NASH) and SARS-CoV-2 ( COVID-19). Enanta is also researching the human metapneumovirus (hMPV).
Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed through its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in many countries as part of its primary treatment for chronic HCV infection under the trade names MAVYRET® (US) and MAVIRET® (ex-US ) (glecaprevir / pibrentasvir). Please visit www.enanta.com for more information.
CONTACT: Media and investors
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES OTHER CLINICAL TRIALS IN HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Enanta Pharmaceuticals, Inc.
Copyright Business Wire 2021.
PUB: 23/08/2021 07: 00 / DISC: 23/08/2021 07:02
Copyright Business Wire 2021.